IPI Legacy Liquidation Co utilizes its proprietary Precision Olfactory Delivery (POD®) technology to administer therapeutics directly into the vascular-rich upper nasal space, enhancing drug absorption and bioavailability. The company focuses on developing transformative therapies for patients with central nervous system diseases, addressing the significant unmet medical needs in this area.
Funding
Funding not disclosed
Founders
Product
Problem
Many therapeutics administered via traditional nasal delivery systems suffer from variable absorption and limited bioavailability due to inconsistent delivery to the optimal absorption sites within the nasal cavity. This can lead to unpredictable clinical responses and reduced efficacy, particularly for central nervous system (CNS) diseases requiring rapid and consistent drug levels.
Solution
IPI Legacy Liquidation Co (formerly Impel Pharmaceuticals) utilizes its proprietary Precision Olfactory Delivery (POD®) technology to administer therapeutics directly into the vascular-rich upper nasal space, enhancing drug absorption and bioavailability. The POD technology is designed to overcome the limitations of traditional nasal sprays by delivering medication to a region of the nasal cavity that offers injection-like absorption, potentially leading to improved clinical outcomes. This targeted delivery aims to achieve rapid absorption and consistent drug biodistribution, with ease of use for patients, providers, or caregivers. The company's lead product, Trudhesa®, is approved for the acute treatment of migraine with or without aura in adults.
Target Audience
The primary target audience includes individuals suffering from migraines, as well as pharmaceutical companies seeking innovative drug delivery methods for CNS and other diseases.
Features
- Precision Olfactory Delivery (POD®) technology for targeted drug delivery to the upper nasal space.
- Designed for rapid absorption and consistent drug bioavailability.
- Non-invasive administration, potentially improving patient compliance.
- Trudhesa® nasal spray (dihydroergotamine mesylate) approved for acute migraine treatment.
- Potential for use with both small and large molecule therapeutics.